# Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan

Source: https://onco.cc/trials/nct07542002/  
OnCo record `nct07542002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) and cAPOX (capecitabine, oxaliplatin) in pancreatic cancer, run by Ningbo Medical Center Lihuili Hospital, now recruiting.

## Summary

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study is a phase 2, interventional study registered as NCT07542002 by Ningbo Medical Center Lihuili Hospital, with a registry enrolment figure of 37 participants, started 2025-03-25 and due to reach its primary completion in 2026-05-31. Interventions recorded: Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.. Conditions listed: Pancreatic Cancer. Primary outcome: The R0 resection rate. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic cancer (arising from the pancreatic ductal epithelium), as assessed by a multidisciplinary team (MDT), with clinical records indicating resectable or borderline resectable pancreatic cancer with high-risk factors". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07542002
- Phase: 2
- Setting: Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
- Sponsor: Ningbo Medical Center Lihuili Hospital
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT07542002: https://clinicaltrials.gov/study/NCT07542002

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07542002.json